EDWARD LAZAGA: Open Payments
NPI 1396729547 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 34 payments from 8 companies in 2025. Trend: 2023 $787 · 2024 $716 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $444 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $216 |
| Travere Therapeutics, Inc. | 4 | $164 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Amgen Inc. | 1 | $16 |
Products named: Kerendia, JARDIANCE, Filspari, FARXIGA, TARPEYO, IBSRELA, LUPKYNIS, KRYSTEXXA.
Industry payments across TX — which companies pay providers there.
